Sionna Therapeutics
Sionna Therapeutics, Inc. (Nasdaq: SION) is a clinical-stage biopharmaceutical company headquartered at 21 Hickory Drive, Waltham, Massachusetts, working to revolutionize the treatment paradigm for cystic fibrosis (CF) by developing novel small molecules that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Building on more than a decade of its co-founders' research, the company advances a pipeline of first-in-class stabilizers of CFTR's nucleotide-binding domain 1 (NBD1) — the domain that carries F508del, the most common CF-causing mutation — including SION-719 and SION-451, alongside a portfolio of complementary CFTR modulators such as SION-2222 (galicaftor) and SION-109 designed to work synergistically with the NBD1 stabilizers. Sionna operates purely as a drug-development organization: its public web presence is a nine-page WordPress marketing site covering science, pipeline, careers, contact and legal material, plus a hosted investor-relations portal. It publishes no developer program, public API, SDK, webhook surface, or machine-readable specification of any kind.
Sionna Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Clinical Trials.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 4
The organization behind the API
Other 3
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.